Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study-Reference-Cited by-同舟云学术

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

Published:2019-11-14 Issue:1 Volume:2 Page:18-25
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheuma

Author:

Mease Philip J.¹^ORCID,Kavanaugh Arthur²,Reimold Andreas³,Tahir Hasan⁴,Rech Juergen⁵^ORCID,Hall Stephen⁶,Geusens Piet⁷,Pellet Pascale⁸,Delicha Eumorphia Maria⁸,Pricop Luminita⁹,Mpofu Shephard⁸,

Affiliation:

1. Swedish Medical Center/Providence St. Joseph Health and University of Washington Seattle Washington USA

2. University of California San Diego San Diego California USA

3. Dallas VA and University of Texas Southwestern Medical Center Dallas Texas USA

4. Whipps Cross University HospitalBarts Health NHS Trust London UK

5. Friedrich‐Alexander‐University Erlangen‐Nürnberg (FAU)Universitätsklinikum Erlangen Erlangen Germany

6. Monash University Melbourne Australia

7. University of Hasselt, Hasselt, Belgium, and Maastricht University Hospital Maastricht Belgium

8. Novartis Pharma AG Basel Switzerland

9. Novartis Pharmaceuticals Corporation East Hannover New Jersey USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11097

Reference21 articles.

1. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

2. Psoriatic arthritis: epidemiology, clinical features, course, and outcome

3. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

4. Prevalence of Joint Disease in Patients with Psoriasis

5. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-17 inhibitors in axial spondyloarthritis. An overview;Expert Opinion on Biological Therapy;2024-08-21

2. Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study;Modern Rheumatology Journal;2024-08-20

3. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort;2024-03-25

4. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension;Seminars in Arthritis and Rheumatism;2023-12

5. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis;Frontiers in Medicine;2023-11-20